Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Health

Pharmion Corporation to Announce First Quarter 2007 Financial Results


Print article Print article
Refer this article Refer to a friend
2007-04-19 00:24:14 -

BOULDER, Colo., April 18 /PRNewswire-FirstCall/ -- Pharmion Corporation will announce its first quarter 2007 financial results on Wednesday, April 25, 2007, after the close of the U.S. financial markets. Pharmion's senior management will host a conference call and live audio webcast to discuss the company's results in greater detail shortly thereafter, at 5:00 p.m. ET on Wednesday, April 25, 2007.

This call is being webcast by Thomson /CCBN and can be accessed at Pharmion's website at http://www.pharmion.com/. Dial-in numbers for the conference call are as follows: participants from

the U.S. 866.203.3436, participants from Europe 617.213.8849, passcode: 87387106.

The webcast is also being distributed over Thomson/CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through Thomson/CCBN's individual investor center at http://www.fulldisclosure.com/ or by visiting any of the investor sites in Thomson/CCBN's Individual Investor Network. Institutional investors can access the call via Thomson/CCBN's password-protected event management site, Street Events (http://www.streetevents.com/).

Pharmion is a biotechnology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com/.

Source: Pharmion Corporation

© PRNewswire

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.


Terms & Conditions | Privacy | About us | Contact PR-inside.com